FDA 483 - Hugel Inc. - February 01, 2024

Hugel, Inc., a drug substance and drug product manufacturer in Chuncheon, Korea, received two observations during an FDA inspection. The firm was cited for not establishing and following procedures to prevent microbiological contamination of sterile drug products, specifically concerning media fills. Additionally, visual inspection procedures were found to be inadequate, particularly regarding ambient lighting.